Background Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the
number of colorectal adenomas in animals and patients with familial adenomatous …

Abstract The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of
the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention …

Background Overexpression of cyclooxygenase 2 (COX-2) has been associated with
colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition …

Background Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny
because of reports suggesting an increased cardiovascular risk associated with their use …

Background—Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal
adenomas but have been associated with increased cardiovascular risk. Methods and …

OBJECTIVES: Subjects in the Prevention of Colorectal Sporadic Adenomatous Polyps
(PreSAP) trial (PRESAP/NCT00141193/www. clinicaltrials. gov) were studied to determine …

Background & Aims: In human and animal studies, nonsteroidal anti-inflammatory drugs
have been associated with a reduced risk of colorectal neoplasia. Although the underlying …

Background Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an
increased risk of thrombotic events, but only limited long-term data have been available for …

BACKGROUND & AIMS:: Colorectal cancer is one of the leading causes of cancer death.
Most colorectal cancers are believed to develop from colorectal adenomas. We examined …

Background Patients with familial adenomatous polyposis have a nearly 100 percent risk of
colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal …